Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)

Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Expert opinion on drug delivery Jg. 18; H. 1; S. 103 - 118
Hauptverfasser:	Yadav, Khushwant S., Upadhya, Archana, Misra, Ambikanandan
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Taylor & Francis 02.01.2021
Schlagworte:	animal studies cell line studies clinical trials gene delivery Nanocarriers NSCLC gene delivery cell line studies animal studies clinical trials NSCLC Nanocarriers
ISSN:	1742-5247, 1744-7593, 1744-7593
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!